Cybin alters state to become Helus Pharma for Nasdaq trip
I'm PortAI, I can summarize articles.
Cybin is rebranding as Helus Pharma and moving its stock listing from NYSE American to Nasdaq Global Market on January 5, 2026. The company will change its stock ticker from "CYBN" to "HELP" and continue to be listed on Cboe Canada. Helus will focus on delivering data for major depressive disorder and generalized anxiety disorder, with significant data releases expected in 2026. The rebranding and stock exchange shift are supported by a $175 million investment from Venrock Healthcare Capital Partners and OrbiMed.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Fiercepharma The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments